Effects of serum cystatin C on risks of cardiovascular events in elderly atrial fibrillation patients without renal insuffciency

Objective To investigate the effects of serum Cystatin C on the risks of cardiovascular events in elderly atrial fbrillation patients without renal insuffciencyeGFR> 60 ml/(min·1.73 m²). Methods Totally 356 elderly non-vavularatrial fbrillation patients without renal insuffciency were selected from July 2008 to June 2010 in this retrospective study. The baseline characteristics and clinical adverse events were recorded. The patients were divided into two groups according to the median value of baseline serum Cystatin C concentration (1.15 mg/L). Multivariate Cox regression analysis was adopted to calculate the adjusted hazard ratio (HR) of elevated serum Cystatin C concentration for clinical adverse events. Results During a mean follow-up period of 37.8 months, 97 patients died and 27 patients died of cardiovascular diseases. A total of 74 patients had thromboembolic events and 56 patients had cardiovascular events. After adjusting for other traditional risk factors, serum Cystatin C ≥ 1.15 mg/Lwas an independent predictor of all-cause death (HR:2.250, 95%CI:1.460-3.468, P< 0.001), cardiovascular death (HR:3.695, 95%CI:1.536-8.889, P=0.004), thromboembolic event (HR:1.725, 95%CI:1.055-2.819, P=0.030) and cardiovascular event (HR:2.345, 95%CI:1.309-4.203, P=0.004). Conclusion Serum Cystatin C ≥ 1.15 mg/L is an predictor of high risks of all-cause death, cardiovascular death, thromboembolic event and cardiovascular event in elderly non-vavular atrial fbrillation patients without renal insuffciency.